MR4.5 Matters: giving Ph+ CML-CP patients the best chance of optimal outcomes

Make MR4.5 the treatment goal for improved patient outcomes1

Lower rate of progression1

With median follow-up of 3 years, assessment of progressions according to response level showed that no patients with confirmed MR4.5 progressed (n=1524)1

Number of patients who progressed after median observation times between 3.8 and 4.7 years1

Improved overall survival1

Patients who achieved MR4.5 (8-year OS advantage of 9% with CCyR [P=.047])1

Improved Overall Survival for Patients who Achieved MR4.51

CML, chronic myeloid leukemia; IS, International Scale; CCyR, complete cytogenetic response; MMR, major molecular response; MR4, BCR-ABLIS ≤ 0.01%; MR4.5, BCR-ABLIS ≤ 0.0032%; OS, overall survival; Ph+, Philadelphia chromosome-positive.

  1. Hehlmann R, et al. J Clin Oncol. 2014;32:415-423.